indonesia
FIND
The Swiss Malaria Group members are operating in almost all malaria endemic countries. With their commitment they are contributing to the global fight against malaria. For more information on our members, please go to the member's website by clicking on the member's logo.
Malaria Innovation Platform - Evaluation of novel malaria diagnostic tools for point-of-care testing
Multi-site clinical evaluation of novel malaria diagnostic tools in malaria-endemic countries to assess their clinical performance for detection of malaria at point-of-care (POC). This study supported product development efforts and provided early stage (TRL~5) technology developers with valuable information on performance and basic feasibility data that helped accelerate development.
Malaria Innovation Platform - Abbott WHO Prequalification evaluation
Clinical performance of Abbott NxTekTM RDTs for detection of Plasmodium infections in patients with symptoms suggestive of malaria to support submission to WHO prequalification.
Malaria Innovation Platform - RapiGEN WHO Prequalification evaluation
Clinical performance of RapiGEN BIOCREDIT Malaria Ag RDTs for detection of Plasmodium infections in patients with symptoms suggestive of malaria to support submission to WHO prequalifictation.
Development of a serological rapid test for risk of P. vivax relapse
A host antibody marker of past P. vivax infection is targeted in a lateral flow assay in development by Mologic (UK). Clinical studies with partners in Indonesia and Australia will evaluate the assay performance in two longitudinal cohort studies monitoring P. vivax clinical exposure and relapse events.
Pays
indonesia united-kingdom japan australia
Impact
1,180 persons
Durée
2015 - ongoing
Activité
Innovation,Diagnosis
Multi-laboratory reproducibility assessment of a portable quantitative G6PD assay
A multi-laboratory assessment of the G6PD STANDARD test (SD Biosensor, South Korea) to evaluate assay repeatability and reproducibility across users and settings. The study uses lyophilised controls to ensure standardized samples are used across all sites, so findings should be validated in fresh samples.
Pays
bangladesh brazil indonesia united-states thailand france
Impact
Control samples only
Durée
2020-2021
Activité
Innovation,Diagnosis
Medicines for Malaria Venture
The Swiss Malaria Group members are operating in almost all malaria endemic countries. With their commitment they are contributing to the global fight against malaria. For more information on our members, please go to the member's website by clicking on the member's logo.
Project 2
Supporting development of a key easy-to-administer and long-protective antimalarial - dihydroartemisinin-piperaquine (Euroartesim).